About this item:

762 Views | 123 Downloads

Author Notes:

Correspondence: Xi Lin, PhD Department of Otolaryngology and Cell Biology Emory University School of Medicine Atlanta, GA 30322; Telephone: 404-727-3723; Fax: 404-727-6256; Email: xlin2@emory.edu

Acknowledgments: We thank Ms. Anne Lin for proofreading the final version of the manuscript.

Disclosures: Drs. Xi Lin and Wenxue Tang own equity in the Otogenetics Corporation, which offers a commercial service for capturing and next-generation sequencing of human genes implicated in syndromic and non-syndromic hearing loss.

The terms of the conflict of interest (COI) arrangement for the two authors have been reviewed and approved by Emory University in accordance with its COI policies.

Subjects:

Research Funding:

This study was supported by grants to Lin from the National Institute on Deafness and other Communication Disorders (NIDCD 4R33DC010476, 1R41DC009713 and RO1 DC006483).

Tang received grant support from NIDCD (R21 DC008672).

This research project was supported in part by the GRA genome center of the Emory University School of Medicine.

Keywords:

  • mutations
  • genes
  • deafness
  • genetics
  • review
  • next-generation sequencing
  • exome
  • gene enrichment

Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities

Tools:

Journal Title:

Hearing Research

Volume:

Volume 288, Number 0

Publisher:

, Pages 67-76

Type of Work:

Article | Post-print: After Peer Review

Abstract:

The goal of sequencing the entire human genome for $1,000 is almost in sight. However, the total costs including DNA sequencing, data management, and analysis to yield a clear data interpretation are unlikely to be lowered significantly any time soon to make studies on a population scale and daily clinical uses feasible. Alternatively, the targeted enrichment of specific groups of disease and biological pathway-focused genes and the capture of up to an entire human exome (~1% of the genome) allowing an unbiased investigation of the complete protein-coding regions in the genome are now routine. Targeted gene capture followed by sequencing with massively parallel next-generation sequencing (NGS) has the advantages of 1) significant cost saving, 2) higher sequencing accuracy because of deeper achievable coverage, 3) a significantly shorter turnaround time, and 4) a more feasible data set for a bioinformatic analysis outcome that is functionally interpretable. Gene capture combined with NGS has allowed a much greater number of samples to be examined than is currently practical with whole-genome sequencing. Such an approach promises to bring a paradigm shift to biomedical research of Mendelian disorders and their clinical diagnoses, ultimately enabling personalized medicine based on one’s genetic profile. In this review, we describe major methodologies currently used for gene capture and detection of genetic variations by NGS. We will highlight applications of this technology in studies of genetic disorders and discuss issues pertaining to applications of this powerful technology in genetic screening and the discovery of genes implicated in syndromic and non-syndromic hearing loss.

Copyright information:

© 2012 Elsevier B.V. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Creative Commons License

Export to EndNote